Development and Launch of Novel Coronavirus Detection Reagents and Establishment of a Stable Supply System
First written in FY2020. 6 of 12 entries say "Restated". Latest entry: FY2025.
1 other company's latest entry also says "Other".
- FY2025Shrinking demand for COVID-19-related productsAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥6,342 million, down 10.5% year on year, due to substantial declines in medical device sales, COVID-19 detection reagent sales and LAMP patent royalty income.」
While the Company had advanced the development, stable supply and global expansion of detection reagents, related sales declined substantially for the full year. - FY2024-Q2RestatedAnnual report
「Revenue from Other (medical devices, genetic testing-related products, etc.) was ¥3,285 million, down 52.9% year on year, due to a substantial decline in sales of COVID-19 detection reagents.」
While the Company had advanced the development and supply of COVID-19 detection reagents, sales in the related category declined 52.9% year on year due to limited demand following the reclassification under the Infectious Diseases Control Law. - FY2024-Q1Limited testing demand following COVID-19's reclassification to Category 5 under the Infectious Diseases Control LawAnnual report
「Revenue for the cumulative first quarter of the current consolidated fiscal year was ¥9,864 million, down 11.1% year on year, as demand for genetic testing became limited following the reclassification of COVID-19 under the Infectious Diseases Control Law, resulting in a substantial decline in sales of LAMP-based COVID-19 genetic testing reagents.」
While the Company had advanced the development, supply and global expansion of detection reagents, demand for genetic testing and sales of the product declined substantially following the reclassification under the Infectious Diseases Control Law. - FY2023AdvancedAnnual report
「In addition, as part of its response to COVID-19, the Company launched the Exdia EK Test series, a high-sensitivity immunochromatographic system capable of testing for COVID-19 and influenza A/B antigens from a single swab specimen.」
In addition to the stable supply and global expansion of detection reagents, the Company progressed to the launch of a product series capable of testing for COVID-19 and influenza A/B from a single swab specimen. - FY2022RestatedAnnual report
「In light of these risks, the Group will work to rapidly monitor developments in each country, respond flexibly to changes in the operating environment, and contribute to society and expand sales through the stable supply and global expansion of COVID-19 detection reagents.」
The Company continued its policy of contributing to society and expanding sales through the stable supply and global expansion of COVID-19 detection reagents. - FY2022-Q3RestatedAnnual report
「In addition, through the stable domestic supply and global expansion of COVID-19 detection reagents, the Company aims to contribute to measures against the disease.」
The Company continued its policy of contributing to measures against infectious diseases through the stable domestic supply and global expansion of COVID-19 detection reagents. - FY2022-Q2RestatedAnnual report
「In addition, through the stable domestic supply and global expansion of COVID-19 detection reagents, the Company aims to contribute to measures against the disease.」
The Company continued its policy of contributing to measures against infectious diseases through the stable domestic supply and global expansion of COVID-19 detection reagents. - FY2022-Q1RestatedAnnual report
「In addition, through the stable domestic supply and global expansion of COVID-19 detection reagents, the Company aims to contribute to measures against the disease.」
The Company continued its policy of contributing to measures against infectious diseases through the stable domestic supply and overseas expansion of COVID-19 detection reagents. - FY2021AdvancedAnnual report
「In addition, the Company obtained the CE mark in November to support overseas expansion.」
For COVID-19 detection reagents, the Company obtained the CE mark in November 2020 for overseas expansion. - FY2021-Q2RestatedAnnual report
「In addition, through the supply of COVID-19 detection reagents, the Company aims to contribute to measures against the disease. Revenue for the cumulative second quarter of the current consolidated fiscal year was ¥17,727 million, down 6.3% year on year, as the substantial increase in sales of COVID-19 detection reagents was offset by the impact of interruptions to various health screenings and screening programs and a decline in the number of outpatients due to the spread of COVID-19.」
The Company continued its policy of contributing to measures against infectious diseases through the supply of detection reagents and stated that sales of detection reagents increased substantially. - FY2021-Q1AdvancedAnnual report
「In addition, through the supply of COVID-19 detection reagents, the Company aims to contribute to measures against the disease. Revenue for the cumulative first quarter of the current consolidated fiscal year was ¥8,214 million, down 11.0% year on year, as the substantial growth in sales of COVID-19 detection reagents and genetic testing equipment was offset by the impact of interruptions to various health screenings and a decline in the number of outpatients due to the spread of COVID-19.」
Following the previous year's development and launch of detection reagents and establishment of a stable supply system, the Company stated that it aims to contribute to measures against infectious diseases through the supply of detection reagents, and that sales of detection reagents and genetic testing equipment increased substantially. - FY2020First statedAnnual report
「In addition, as part of its response to the rapidly spreading COVID-19 pandemic, the Company worked to accelerate development of LAMP-based detection reagents for the virus, launching the "Loopamp 2019-nCoV Detection Reagent Kit" (research-use reagent) in March 2020 and the "Loopamp COVID-19 2019 (SARS-CoV-2) Detection Reagent Kit" (in vitro diagnostic medical device) in April of the same year.」
For COVID-19 detection reagents, the Company described for the first time in an integrated manner its participation in an AMED project, the launch of research-use reagents and in vitro diagnostic medical devices, and the establishment of a stable supply system.